American Century Companies Inc. Raises Stock Position in Zentalis Pharmaceuticals, Inc. $ZNTL

American Century Companies Inc. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 46.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,900 shares of the company’s stock after acquiring an additional 14,816 shares during the quarter. American Century Companies Inc. owned approximately 0.07% of Zentalis Pharmaceuticals worth $75,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. D. E. Shaw & Co. Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 9.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock valued at $3,756,000 after acquiring an additional 110,882 shares during the period. Integral Health Asset Management LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $3,182,000. Millennium Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 8.1% during the 4th quarter. Millennium Management LLC now owns 957,563 shares of the company’s stock worth $2,901,000 after purchasing an additional 71,477 shares during the period. Federated Hermes Inc. grew its stake in Zentalis Pharmaceuticals by 52.3% in the 1st quarter. Federated Hermes Inc. now owns 752,517 shares of the company’s stock valued at $1,197,000 after acquiring an additional 258,535 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Zentalis Pharmaceuticals by 35.2% in the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock valued at $1,943,000 after acquiring an additional 167,062 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages recently commented on ZNTL. HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.20.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $1.75 on Monday. The company has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.49. The firm has a market capitalization of $126.25 million, a P/E ratio of -0.77 and a beta of 1.76. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.19. As a group, sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.